WO2001076597A3 - A method of administering an antitumour compound using a polymer-camptothecin conjugate - Google Patents

A method of administering an antitumour compound using a polymer-camptothecin conjugate Download PDF

Info

Publication number
WO2001076597A3
WO2001076597A3 PCT/EP2001/003765 EP0103765W WO0176597A3 WO 2001076597 A3 WO2001076597 A3 WO 2001076597A3 EP 0103765 W EP0103765 W EP 0103765W WO 0176597 A3 WO0176597 A3 WO 0176597A3
Authority
WO
WIPO (PCT)
Prior art keywords
weeks
polymer
amount
administering
compound
Prior art date
Application number
PCT/EP2001/003765
Other languages
French (fr)
Other versions
WO2001076597A2 (en
Inventor
Paola Gerletti
Maria Grazia Porro
William Speed
Original Assignee
Pharmacia & Upjohn Spa
Paola Gerletti
Maria Grazia Porro
William Speed
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Spa, Paola Gerletti, Maria Grazia Porro, William Speed filed Critical Pharmacia & Upjohn Spa
Priority to AU54769/01A priority Critical patent/AU5476901A/en
Publication of WO2001076597A2 publication Critical patent/WO2001076597A2/en
Publication of WO2001076597A3 publication Critical patent/WO2001076597A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Abstract

Use of MAG-CPT, a polymer-bound conjugate described in WO99/17804, in the manufacture of a medicament for the treatment of a tumour by a dose schedule comprising administration of the said compound by intravenous infusion daily for three consecutive days every 4 weeks in an amount of from 15 to 100 mg/m2/day, or weekly for 2 or 3 consecutive weeks every 4 weeks in an amount of from 20 to 250 mg/m2/week, or as a single administration every week or every four weeks in an amount of from 20 to 240 mg/m2. The method is preferably for the treatment of solid tumours, such as cancer of the gastro-intestinal tract (e.g. colo-rectal, pancreatic, gastric and oesophageal), ovarian, mammary, prostatic, lung, kidney and melanoma.
PCT/EP2001/003765 2000-04-11 2001-04-03 A method of administering an antitumour compound using a polymer-camptothecin conjugate WO2001076597A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU54769/01A AU5476901A (en) 2000-04-11 2001-04-03 A method of administering an antitumour compound

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0008928.4 2000-04-11
GBGB0008928.4A GB0008928D0 (en) 2000-04-11 2000-04-11 A method of administering an antitumour compound

Publications (2)

Publication Number Publication Date
WO2001076597A2 WO2001076597A2 (en) 2001-10-18
WO2001076597A3 true WO2001076597A3 (en) 2002-05-16

Family

ID=9889704

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/003765 WO2001076597A2 (en) 2000-04-11 2001-04-03 A method of administering an antitumour compound using a polymer-camptothecin conjugate

Country Status (3)

Country Link
AU (1) AU5476901A (en)
GB (1) GB0008928D0 (en)
WO (1) WO2001076597A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2408387C2 (en) 2004-04-27 2011-01-10 Веллстат Байолоджикс Корпорейшн Virus and camptothecin based treatment of malignant growth
ATE540698T1 (en) 2005-07-14 2012-01-15 Wellstat Biologics Corp CANCER TREATMENT WITH VIRUSES, FLUOROPYRIMIDINES AND CAMPTOTHECINES
CA2995029C (en) 2015-09-25 2022-10-25 Zy Therapeutics Inc. Drug formulation based on particulates comprising polysaccharide-vitamin conjugate

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773522A (en) * 1993-10-08 1998-06-30 Pharmacia S.P.A. Polymer-bound camptothecin derivatives
WO1999017805A1 (en) * 1997-10-03 1999-04-15 Pharmacia & Upjohn S.P.A. Bioactive derivatives of camptothecin
WO1999017804A1 (en) * 1997-10-03 1999-04-15 Pharmacia & Upjohn S.P.A. Polymeric derivatives of camptothecins
WO2001000240A2 (en) * 1999-06-29 2001-01-04 Pharmacia & Upjohn Spa Antitumor compound

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773522A (en) * 1993-10-08 1998-06-30 Pharmacia S.P.A. Polymer-bound camptothecin derivatives
WO1999017805A1 (en) * 1997-10-03 1999-04-15 Pharmacia & Upjohn S.P.A. Bioactive derivatives of camptothecin
WO1999017804A1 (en) * 1997-10-03 1999-04-15 Pharmacia & Upjohn S.P.A. Polymeric derivatives of camptothecins
WO2001000240A2 (en) * 1999-06-29 2001-01-04 Pharmacia & Upjohn Spa Antitumor compound

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CAIOLFA V R ET AL: "Polymer-bound camptothecin: initial biodistribution and antitumour activity studies", JOURNAL OF CONTROLLED RELEASE, ELSEVIER SCIENCE PUBLISHERS B.V., AMSTERDAM, NL, vol. 65, no. 1-2, March 2000 (2000-03-01), pages 105 - 119, XP004190316, ISSN: 0168-3659 *

Also Published As

Publication number Publication date
WO2001076597A2 (en) 2001-10-18
GB0008928D0 (en) 2000-05-31
AU5476901A (en) 2001-10-23

Similar Documents

Publication Publication Date Title
CZ309247B6 (en) 40-O- (2-hydroxyethyl) rapamycin for use as the sole active ingredient in treating a solid tumour
IL148782A0 (en) Drugs for the treatment of malignant tumours
YU23202A (en) Drugs for the treatment of malignant tumors
CA2301057A1 (en) A method of administering liposomal encapsulated taxane
CA2464758A1 (en) Combination therapy comprising zd6474 and a taxane
CA2428160A1 (en) Compositions for antitumor treatment containing ecteinascidin 743
AU3331499A (en) Antitumor composition containing a synergistic combination of an anthracycline derivative with a camptothecin derivate
HK1068606A1 (en) Novel aminobenzoephenones
IL136733A0 (en) Pharmaceutical composition containing sibutramine and orlistat
PL342614A1 (en) Anticarcinogenic drugs
JO2390B1 (en) Lipid lowering biphenulcarboxamides
WO2001076597A3 (en) A method of administering an antitumour compound using a polymer-camptothecin conjugate
WO2002064214A3 (en) Anti cancer combination of substituted pyrroles and paclitaxel
DE60222383D1 (en) MEDICAMENT FOR THE ADMINISTRATION OF AMIFOSTIN AND RELATED ACTIVE SUBSTANCES
AU2162202A (en) Antitumor therapy comprising distamycin derivatives
AU2001281867B2 (en) Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and alkylating agents
MXPA01012936A (en) Pharmaceutical composition containing sibutramine and orlistat.
AU2001281867A1 (en) Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and alkylating agents
WO2002040477A3 (en) Saframycins, analogues and uses thereof
AU2003285351A8 (en) Agent having a destructive effect on malignant tumors and method for the production thereof
WO2002017962A3 (en) Chemoprotectant for gastric toxicity
WO2001000187A3 (en) Pharmaceutical composition containing sibutramine and a lipase inhibitor
TW200633722A (en) Complexes made using low solubility drugs
MY126998A (en) Substituted pyrroles.
WO2003074049A1 (en) Antitumor agents

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP